Microglia drive amyloid-β clearance in immunized patients with Alzheimer’s disease

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-04-22 DOI:10.1038/s41591-025-03677-9

引用次数: 0

Abstract

Microglia have a central role in the clearance of amyloid-β after immunotherapy in Alzheimer’s disease. By integrating spatial transcriptomics and single-cell RNA sequencing, we identified distinct microglial states that mediate removal of amyloid-β. APOE and TREM2 emerged as key regulators of amyloid-β clearance and indicators of treatment response, and thereby represent potential therapeutic targets.

Abstract Image

查看原文本刊更多论文

小胶质细胞驱动阿尔茨海默病患者的淀粉样蛋白-β清除

小胶质细胞在阿尔茨海默病免疫治疗后淀粉样蛋白-β的清除中起中心作用。通过整合空间转录组学和单细胞RNA测序，我们确定了介导淀粉样蛋白-β去除的不同小胶质状态。APOE和TREM2是淀粉样蛋白-β清除的关键调节因子和治疗反应的指标，因此代表了潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.